Title: Independent contributions of functional class, comorbidity, and frailty to health status

in elderly adults with heart failure

Running title: Predictors of health status in heart failure

Authors: Nguyen Le Huy Hoang[1*], Pham Thi Ngoc Anh[1], Trinh Cong Tuan[1], Than Ha Ngoc

The[1,2], Nguyen Ngoc Hoanh My Tien[1,2], and Pham Huy Tung[3]

Work performed at Thong Nhat Hospital, Ho Chi Minh City, Vietnam.

Affiliation:

[1]School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi

Minh City, Vietnam.

[2]Department of Geriatrics and Palliative Care, University Medical Centre Ho Chi Minh City,

Ho Chi Minh City, Vietnam.

[3]Department of Radiology, Thong Nhat Hospital, Ho Chi Minh City, Vietnam.

*Corresponding author:

Nguyen Le Huy Hoang, MD, MSc

Position: cardiologist and geriatrician

Institution: School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City

Address: 217 Hong Bang Street, Cho Lon Ward, Ho Chi Minh City, Vietnam

Phone number: +84 946 639 943

Email: lucian.nguyen@icloud.com

ORCID ID: 0009-0002-2791-2838

Other authors:

Pham Thi Ngoc Anh, MD, MSc

Position: physician

Institution: School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City

Address: 217 Hong Bang Street, Cho Lon Ward, Ho Chi Minh City, Vietnam

Email: phamthingocanh798@gmail.com

Trinh Cong Tuan, MD, MSc

Position: physician

Institution: School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City

Address: 217 Hong Bang Street, Cho Lon Ward, Ho Chi Minh City, Vietnam

Email: tringcongtuan@gmail.com

Than Ha Ngoc The, MD, PhD

Position: lecturer and physician

Institution: School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City

and Department of Geriatrics and Palliative Care, University Medical Centre Ho Chi Minh

City

Address: 217 Hong Bang Street, Cho Lon Ward, Ho Chi Minh City, Vietnam

Email: the.thn@umc.edu.vn

Nguyen Ngoc Hoanh My Tien, MD, MSc, Specialist Level 2

Position: lecturer and physician

Institution: School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City

and Department of Geriatrics and Palliative Care, University Medical Centre Ho Chi Minh

City

Address: 217 Hong Bang Street, Cho Lon Ward, Ho Chi Minh City, Vietnam

Email: tien.nnhm@umc.edu.vn

Pham Huy Tung, MD, MSc

Position: radiologist

Institution: Department of Radiology, Thong Nhat Hospital

Address: 1 Ly Thuong Kiet Street, Tan Son Nhat Ward, Ho Chi Minh City, Vietnam

Email: tunghuy516@gmail.com

Total word count: 3361 words

Number of Figures and Table: 7 main tables, 4 supplementary tables, 2 supplementary figures.

Abstract

Aims

56 This study identified and quantified independent predictors of health status among older

57 ambulatory adults with chronic heart failure in an Asian population, hypothesizing that

58 systemic burden indicators would predict health status independently of ejection fraction.

Methods

This cross-sectional observational study enrolled 150 consecutive Vietnamese patients aged

60 years or older with chronic heart failure attending a cardiology clinic between August

2024 and March 2025. Health status was assessed using the validated Vietnamese Kansas

City Cardiomyopathy Questionnaire-12. Multivariable linear regression models examined

associations between KCCQ-12 scores and clinical variables including left ventricular

ejection fraction, New York Heart Association functional class, Clinical Frailty Scale scores,

Charlson Comorbidity Index, and demographics. Secondary analyses evaluated domain-

specific scores and phenotype-stratified associations.

Results

The median age was 75 years, and median KCCQ-12 summary score was 68. Multivariable

regression explained 77% of variance in health status. Advanced NYHA functional class,

higher comorbidity burden, and frailty independently predicted lower KCCQ-12 scores, while

male sex was associated with higher scores. Left ventricular ejection fraction and N-terminal

pro-B-type natriuretic peptide showed no significant association with health status. These

patterns remained consistent across all KCCQ-12 domains and heart failure phenotypes.

Nutritional status correlated with health status univariately but was subsumed by frailty in

multivariable models.

Conclusions

Geriatric syndromes, including frailty, multimorbidity, and functional limitation, determine

patient-reported health status in older Asian adults with heart failure independent of cardiac-

specific indices. These findings support integrating systematic frailty assessment and

functional preservation into routine cardiovascular care for aging Asian populations.

Keywords

• Heart failure

• Patient-reported outcome measures

• Frailty

• Comorbidity

• Left ventricular ejection fraction

Introduction

Heart failure affects an estimated 64 million individuals globally,[1] with substantial regional variation in disease burden and outcomes. The absolute number of prevalent cases has increased across all Asian regions from 1990 to 2019, reflecting population aging and improved survival.[2] This epidemiologic shift has prompted clinical guidelines to emphasize routine monitoring of patient-reported health status using validated instruments,[3] recognizing that enhancing functional capacity and quality of life are now critical management objectives alongside mortality reduction.[3] The Kansas City Cardiomyopathy Questionnaire (KCCQ) and its abbreviated 12-item version have demonstrated robust predictive validity for hospitalizations and mortality in diverse settings,[4] establishing them as preferred disease-specific health status measures in contemporary practice and research.[5]

Patient-reported health status correlates more strongly with clinical outcomes than traditional cardiac metrics, a phenomenon particularly evident in the discordance between left ventricular ejection fraction and symptom burden.[6] Recent machine learning models demonstrate that KCCQ scores dominate predictions of 90-day hospitalizations and mortality when compared with conventional clinical variables.[7] Emerging evidence identifies functional class, multimorbidity, frailty, and nutritional status as key determinants of health status in heart failure populations.[8] Frailty affects at least half of heart failure patients[9] and independently predicts all-cause mortality,[9] with nutritional status and frailty demonstrating synergistic prognostic effects.[10] These systemic indicators often outperform ejection fraction in predicting patient-centered outcomes.[6]

Most predictive frameworks for health status derive from Western cohorts, yet Asian patients exhibit distinct clinical phenotypes and risk profiles that may limit generalizability.[11] Regional analyses reveal substantial ethnic differences in comorbidity patterns, with Malays

and Indians demonstrating higher odds of coronary artery disease compared with Chinese

populations, while Korean and Japanese patients show markedly lower rates.[11] Despite

representing a substantial proportion of the global heart failure burden, Asian populations

remain underrepresented in studies examining health status determinants.[12] Furthermore,

older ambulatory patients are frequently excluded from clinical trials, creating uncertainty

regarding factors influencing health status in this vulnerable demographic.[13]

This study aimed to identify and quantify independent predictors of health status among older

ambulatory adults with chronic heart failure in an Asian population. We hypothesized that

indicators of systemic burden, including functional class, comorbidity, frailty, and nutritional

status, would predict KCCQ-12 scores independently of ejection fraction. We further

examined whether these associations remained consistent across health status domains and

heart failure phenotypes.

Methods

Study design and participants

This analytical observational, cross-sectional study followed Strengthening the Reporting of

Observational Studies in Epidemiology (STROBE) guidelines for reporting.[14] The source

population comprised consecutive patients aged 60 years or older with chronic HF

(diagnosed according to ESC guidelines for at least 3 months)[15] attending Thong Nhat

Hospital cardiology clinic between August 2024 and March 2025. Patients were excluded if

they had acute decompensated heart failure (defined as hospitalization or urgent intravenous

diuretic use within the previous 4 weeks) or severe cognitive impairment preventing

informed consent or questionnaire completion. Sample size calculations used two

approaches: first, estimating mean KCCQ-12 scores with 5-point precision[16] (assuming a

standard deviation of 25 and 95% confidence level) required 97 participants; second, Green's

formula for testing regression coefficients[17] with six predictors (assuming a medium effect

size, power of 0.80, and $\alpha = 0.05$) required 110 participants. The final cohort of 150

participants exceeded both requirements. Ethical approval was obtained from the University

of Medicine and Pharmacy at Ho Chi Minh City (2118/HDDD-DHYD) and Thong Nhat

Hospital (121/2024/CN-BVTN-HDDD). The study complied with the Declaration of

Helsinki,[18] and all participants provided written informed consent before enrollment.

Data collection and measurements

All procedures were completed during a single outpatient visit at Thong Nhat Hospital

cardiology clinic. During the visit, trained staff conducted face-to-face interviews in

Vietnamese and administered several validated instruments, including the Vietnamese

KCCQ-12[16,19] and the Clinical Frailty Scale (CFS),[20] using structured case report

forms developed for this study. Staff provided standardised instructions for all

instruments and, where feasible, remained blinded to clinical data to minimise

information bias. A cardiologist, blinded to the questionnaire results, performed

clinical assessments and assigned NYHA functional class.[21] Data for the Charlson

Comorbidity Index (CCI), N-terminal pro–B-type natriuretic peptide (NT-proBNP)

levels, and baseline LVEF were abstracted from medical records (selecting the most

recent values within 3 months prior to the visit). Staff received protocol training with

competency assessments. Data were entered into an electronic case report form with

automated range and consistency checks. Analyses used anonymized data.

Variable definitions

Primary and secondary outcomes

Participants completed a validated Vietnamese version of the KCCQ-12 during a

baseline visit before clinical assessment. Scores for the four domains (physical

limitation, symptom frequency, quality of life, and social limitation) were transformed

to a 0–100 scale, with higher scores indicating better health. The primary outcome was

the overall summary score, calculated as the mean of the available domain scores. The

individual domain scores served as secondary outcomes. We prespecified a minimal

clinically important difference of 5 or more points for the overall score, which is a

conservative estimate consistent with published data.[22]

Key explanatory variables

LVEF was treated as a continuous variable in the primary regression model. Functional

capacity was defined by the NYHA functional class, which we dichotomised for regression

into mild (classes I–II) and advanced (classes III–IV) limitation.[21] The CCI represented the

comorbidity burden.[23] While treated as a continuous variable in the primary regression model,

for descriptive analyses, scores were stratified into low burden (scores 3–5), medium burden

(6–7), and high burden (≥8). This categorisation was based on the distribution of scores

within the study cohort rather than pre-specified a priori cut-points. Frailty was defined as a

score of 5 or higher on the 9-point CFS. This threshold is widely used and validated for

identifying at least mild frailty in older adults and is associated with adverse outcomes.

Other covariates

For descriptive purposes, we classified HF phenotype according to 2021 European Society

of Cardiology guidelines based on LVEF: reduced (HFrEF; ≤40%), mildly reduced

(HFmrEF; 41–49%), or preserved (HFpEF; ≥50%).[15] In the primary model, LVEF was

treated as a continuous variable. We recorded demographics (age, sex), lifestyle factors

(smoking, alcohol use), and clinical measurements, including body mass index, resting heart

rate and blood pressure (calculated as the mean of two measurements), and NT-proBNP

concentrations. Polypharmacy was defined as using five or more concurrent medications.

We also counted the number of prescribed foundational HF drug classes (renin-angiotensin

system inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose

cotransporter-2 inhibitors; range 0–4). Functional status was assessed using the Katz Index

of Independence in Activities of Daily Living,[24] and nutritional status was evaluated with the

Mini Nutritional Assessment Short-Form.[25]

Statistical analysis

Statistical analyses were performed using Stata version 19.5 (StataCorp, College Station,

Texas, USA). Categorical variables were summarized as counts and percentages. Continuous

variables were assessed for normality using the Shapiro-Wilk test and histogram inspection,

then reported as mean with standard deviation or median with interquartile range.

Descriptive trends across ordered groups were tested using the Jonckheere-Terpstra test for

continuous or ordinal outcomes and the Cochran-Armitage test for binary outcomes. KCCQ-

12 summary and domain scores were compared across categories using the Mann-Whitney

U test for two groups and the Jonckheere-Terpstra test for three or more ordered groups. The

primary analysis used a multivariable linear regression model to identify predictors of the

KCCQ-12 overall summary score. To separate chronological age from cumulative

comorbidity, the model included age and the CCI as independent continuous predictors

alongside LVEF, dichotomized NYHA functional class, binary frailty status, and sex. Results

were expressed as adjusted regression coefficients with 95% confidence intervals using

robust standard errors. Model diagnostics included residual plots for linearity and normality

and variance inflation factors for multicollinearity.

Exploratory analyses stratified the multivariable regression model by HF phenotype (HFrEF,

HFmrEF, and HFpEF) to examine predictor associations, with interaction p-values

calculated to test for heterogeneity; however, these results are descriptive as the study was

not powered for subgroup interactions. Secondary analyses evaluated the independent

contribution of nutritional status (MNA-SF score) to health status and tested the robustness

of findings through three sensitivity analyses: adjusting for log-transformed NT-proBNP to

control for hemodynamic severity, excluding NYHA class to address potential circularity

with patient-reported outcomes, and substituting frailty with nutritional status to assess

systemic vulnerability across domains. All analyses utilized complete-case data; details

regarding study exclusions due to missing data are provided in the enrolment flow diagram.

A two-sided p-value less than 0.05 defined statistical significance, and no adjustments were

made for multiple comparisons in exploratory analyses.

Results

Cohort and baseline description

The study cohort comprised 150 older adults with HF, categorized into three phenotype

groups (Supplementary Figure 1). The median age was 75 years, with patients in the HFpEF

group significantly older than those in the HFrEF group. Geriatric syndromes such as

malnutrition, frailty, and limitations in daily activities were prevalent across the cohort. Most

patients had moderate-to-high comorbidity burden and were on multiple medications. The

proportion of patients with high comorbidity burden appeared to increase from the HFrEF to

the HFpEF phenotype, though this trend was not statistically significant. Common

comorbidities included hypertension, coronary artery disease, and dyslipidemia. Notably, the

prevalence of atrial fibrillation increased significantly from the HFrEF to the HFpEF group

(Table 1). Among patients with HFrEF, the prescription of foundational therapies was

common. The majority were on combination therapy, with most receiving two to four

different drug classes (Supplementary Table 1).

Systemic burden and health status independent of ejection fraction

The median KCCQ-12 summary score was 68 and did not differ across HF phenotypes.

Health status was poorer in patients with advanced NYHA functional class, frailty, higher

comorbidity burden, and females (Table 2). A multivariable regression model explained 77%

of variance in KCCQ-12 scores. Higher NYHA functional class, increased comorbidity

burden, and frailty were significant predictors of poorer health status, while male sex was

associated with higher scores (Table 3, Supplementary Figure 2). Age and LVEF were not

significant predictors.

Systemic factors and health status domain scores

Consistent with the primary outcome, no significant trend was observed across HF

phenotypes for any KCCQ-12 domain scores, including physical limitation, symptom

frequency, quality of life, and social limitation. Subgroup analyses revealed consistent

patterns of poorer health status, with patients in advanced NYHA functional classes, frail

individuals, those with an increasing comorbidity burden, and females reporting

significantly lower scores across all four domains (Table 4).

Nutritional status as independent predictor of health status

In the multivariable model evaluating nutritional status, the model explained 77% of variance

in KCCQ-12 scores (Table 4). Nutritional status (MNA-SF) was not a significant independent

predictor of health status after adjusting for frailty and other systemic factors. The established

systemic predictors remained robust in this expanded model. Advanced NYHA functional

class, increasing comorbidity burden, and the presence of frailty continued to significantly

predict poorer health status. Male sex was associated with higher scores, while LVEF and age

showed no significant association.

Phenotype-specific associations between systemic factors and health status

Multivariable linear regression models stratified by HF phenotype explained a substantial

proportion of variance in KCCQ-12 scores across all three groups (Table 5). In both HFrEF

and HFpEF, more advanced NYHA class, frailty, and higher comorbidity burden were

independent predictors of poorer health status. Among patients with HFpEF, male sex was

also associated with higher scores. In the HFmrEF group, only higher comorbidity burden

independently predicted lower health status. Health status declined more steeply with

increasing comorbidities in HFmrEF than in HFrEF (Table 6, Table 7).

262 Systemic predictors independent of NT-proBNP levels

In the sensitivity analysis incorporating log-transformed NT-proBNP to adjust for

hemodynamic stress, model fit improved minimally compared to the primary model

(Supplementary Table 2). NT-proBNP levels were not significantly associated with KCCQ-12

scores. The associations between systemic factors and health status remained consistent.

Higher NYHA functional class, greater comorbidity burden, and frailty remained significant

independent predictors of lower health status scores. LVEF was not significantly associated

with health status. Model assumptions of homoscedasticity, linearity, and residual normality

were satisfied.

271 Objective systemic factors excluding functional class

In the sensitivity analysis excluding NYHA functional class, the model explained 66% of

variance in KCCQ-12 scores, reduced from the primary model (Supplementary Table 3).

Systemic factors remained significant predictors. The association between frailty and health

status was larger in this model compared to the primary analysis. Greater comorbidity burden

remained significantly associated with lower health status scores. Male sex was associated

with higher scores, while LVEF and age were not significantly associated with health status.

278 Nutritional status substitution for frailty assessment

In the sensitivity analysis replacing frailty with nutritional status, the model explained 75% of

variance in KCCQ-12 scores. Nutritional status (MNA-SF) was not significantly associated

with health status (Supplementary Table 4). Other systemic predictors remained significant,

including higher NYHA functional class and greater comorbidity burden, both associated

with lower health status scores. LVEF and age were not significantly associated with health

status. Male sex was also not significantly associated with health status in this model.

Discussion

Summary of key findings

This study examined health status determinants in 150 consecutively enrolled older

Vietnamese adults with chronic heart failure (median age 75 years) using the Kansas City

Cardiomyopathy Questionnaire-12. Multivariable regression analysis demonstrated that

geriatric syndromes, rather than cardiac-specific indices, determined patient-reported health

status. Frailty (Clinical Frailty Scale score of 5 or higher), comorbidity burden (Charlson

Comorbidity Index), and functional capacity (New York Heart Association class)

independently predicted KCCQ-12 scores, collectively explaining approximately 77% of

variance. Left ventricular ejection fraction and N-terminal pro-B-type natriuretic peptide

showed no significant independent association with health status across all heart failure

phenotypes. Nutritional status correlated with health status in univariate analyses but was

subsumed by frailty in multivariable models, indicating frailty integrates catabolic decline,

functional loss, and nutritional vulnerability. Male patients reported consistently better health

status scores than females independent of clinical severity. These findings support a geriatric

cardiology model prioritizing functional preservation and holistic assessment over isolated

cardiac metrics for older Asian adults.

The discordance between hemodynamics and health status

The absence of statistical association between left ventricular ejection fraction or N-terminal

pro-B-type natriuretic peptide and KCCQ-12 scores challenges the conventional assumption

that symptom severity reflects cardiac dysfunction. Symptom burden in older adults is

primarily driven by peripheral factors including skeletal muscle dysfunction, endothelial

abnormalities, and impaired oxygen extraction rather than central hemodynamic

inadequacy.[26] Chronic heart failure induces skeletal myopathy characterized by fiber-type

shifts, mitochondrial dysfunction, and reduced capillary density.[27] In Asian populations with

lower baseline muscle mass, progression to sarcopenia occurs earlier and more severely,

leading to early anaerobic metabolism and muscle ergoreflex activation during minimal

exertion.[28] Consequently, patients may demonstrate improved left ventricular ejection

fraction via guideline-directed medical therapy yet remain symptomatic if peripheral

metabolic capacity remains compromised. Additionally, left ventricular ejection fraction is a

load-dependent volumetric measure that fails to capture longitudinal strain, diastolic

relaxation abnormalities, or left atrial mechanics.[29]

N-terminal pro-B-type natriuretic peptide, while indicating wall tension and volume overload,

does not reflect functional adaptation or psychosocial resilience. Older adults with

chronically elevated filling pressures often adapt by restricting physical activity to avoid

dyspnea, reporting fewer symptoms despite elevated biomarker levels. Furthermore, N-

terminal pro-B-type natriuretic peptide levels are influenced by renal dysfunction, atrial

fibrillation, anemia, and age independent of heart failure severity.[30] The decoupling of central

hemodynamics from symptoms supports the peripheral hypothesis, suggesting that

interventions targeting skeletal muscle and metabolic competence, such as resistance training

and nutritional supplementation, may improve health status more effectively than further

titration of hemodynamically active medications in older Asian adults.

The dominant role of frailty and geriatric syndromes

Frailty is a central, independent determinant of health status in older adults with heart failure.

The strong association between Clinical Frailty Scale scores and KCCQ-12 domains

illustrates that frailty amplifies symptom burden beyond the effects of age or comorbidity

alone. Frailty represents a multidimensional physiological vulnerability involving

inflammation, sarcopenia, and loss of homeostatic reserve that is distinct from chronological

aging or the presence of multiple diseases.[31] The prevalence of frailty in this cohort was 36

percent, emphasizing the significance of this syndrome even in populations with lower BMI,

where sarcopenia and functional decline can be masked by a lean phenotype.

While nutritional status showed significance in univariate analyses, its predictive value was

subsumed by frailty in multivariable models. Frailty integrates nutritional decline with

cognitive impairment, physical limitations, and comorbidities, making it a superior tool for

rapid risk stratification in outpatient settings.[32] However, nutritional screening remains

valuable to identify reversible contributors to frailty. The high impact of frailty in Vietnamese

patients may reflect regional factors including limited access to preventive geriatric care and

lifelong nutritional and infectious exposures, which accelerate onset and severity. In Asian

settings, familial dependency magnifies the functional and social consequences of frailty.

Integrating frailty into routine assessment, and adjusting management intensity based on

frailty severity, is critical. Robust patients benefit from guideline-directed therapy, while frail

patients require geriatric-focused interventions, including physical rehabilitation,

deprescribing, and individualized care planning.[15]

Demographic and phenotypic nuances

Male sex was associated with health status scores approximately 3 points higher than females

after adjusting for other factors. Biological explanations include greater skeletal muscle mass

providing metabolic reserve, higher hemoglobin levels, and reduced diastolic stiffness in

men.[33] However, sociocultural factors likely contribute substantially in Asian populations,

where older men may underreport symptoms due to cultural stoicism while women

experience greater physical and emotional strain from dual roles as patients and caregivers.

Women demonstrate higher rates of depression and anxiety in heart failure, which

independently suppresses health status scores.[34] The female disadvantage in heart failure with

preserved ejection fraction is particularly pronounced, as older women experience

disproportionate symptomatic intolerance due to arterial stiffening and ventricular-arterial

uncoupling.[34]

Heart failure with mildly reduced ejection fraction displayed a distinct profile where

comorbidity burden was the dominant health status predictor, with a regression coefficient

more than double that of reduced or preserved ejection fraction phenotypes. This suggests

symptoms in mildly reduced ejection fraction result from cumulative mild organ dysfunctions

rather than isolated cardiac impairment. Effective quality of life improvement may require

aggressive non-cardiac comorbidity management including diabetes control, anemia

correction, and pulmonary disease treatment rather than focusing solely on heart failure

pharmacotherapy.

The high multimorbidity burden (median Charlson Comorbidity Index of 7) reflects

Southeast Asia's epidemiological transition, where heart failure populations exhibit complex

admixtures of hypertension, diabetes, infectious disease histories, and lifestyle diseases.[35] The

exceptionally high burden of diabetes and chronic kidney disease necessitates

multimorbidity-focused care plans rather than disease-specific guidelines.

Strengths and limitations

This study addresses gaps in heart failure literature by enrolling consecutive older adults

(aged 60 years or older) in a real-world Vietnamese ambulatory setting, a population

underrepresented in North American and European trials. Simultaneous collection of

clinician-reported, patient-reported, and objective measures enables comprehensive

assessment of health status determinants. The Vietnamese-validated KCCQ-12 ensures

cultural and linguistic appropriateness. Explicit inclusion of frailty and nutritional assessment

bridges cardiology and geriatrics. Robust associations despite modest sample size reflect

substantial effect sizes.

Sample size limited subgroup analysis power, particularly for mildly reduced ejection

fraction. Cross-sectional design precludes causal inference regarding frailty and health status.

Survivorship and referral bias may exist, as ambulatory patients may be healthier than

homebound individuals, potentially underestimating frailty impact. Unmeasured variables

including socioeconomic status, health literacy, family support, social isolation, and

depression may contribute to residual confounding. Nevertheless, robustness of core

associations across sensitivity analyses supports reliability and generalizability to similar

urban Asian populations.

Future perspectives and clinical implications

These findings support routine frailty screening using the Clinical Frailty Scale in Asian heart

failure clinics. Patient-reported outcomes should replace left ventricular ejection fraction as

therapeutic success metrics in older adults. International guidelines should mandate frailty

assessment and incorporate patient-reported outcomes as primary endpoints for Asian

populations.[3] Future research must test frailty-targeted interventions, including nutritional

supplementation and resistance training, through randomized trials. Longitudinal studies

examining social determinants and multigenerational cohabitation impacts on frailty

progression are essential for developing effective community-based interventions.

Conclusion

This study demonstrates that left ventricular ejection fraction and N-terminal pro-B-type

natriuretic peptide do not predict health status in older Asian adults with heart failure.

Geriatric syndromes including frailty, multimorbidity, and functional limitation determine

patient-reported outcomes. These findings support integrating geriatric principles into

cardiovascular practice through systematic frailty assessment and functional preservation.

Optimizing heart failure care in aging Asian populations requires holistic, multidisciplinary

approaches addressing frailty with equivalent rigor as hemodynamic management.

Author contributions

All authors approved the final submitted version and any revised versions. Nguyen Le Huy

Hoang is the guarantor with full data access and responsibility for accuracy.

Acknowledgements

We thank the patients and their families for participating in this study. We are grateful to the

clinicians, echocardiography technologists, and nursing staff at Thong Nhat Hospital for their

support with patient recruitment, clinical assessments, and echocardiographic evaluations. We

acknowledge the use of the KCCQ-12, licensed from CV Outcomes, Inc. (Kansas City,

Missouri, USA).

Funding

None declared.

Declaration of interest

None declared.

Data availability statement

The data that support the findings of this study are available from the corresponding author,

Nguyen Le Huy Hoang, upon reasonable request. The data are not publicly available due to

restrictions protecting patient privacy.

References

1. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden

of heart failure: a comprehensive and updated review of epidemiology. *Cardiovasc Res*.

2022;118(17):3272-3287. doi:10.1093/cvr/cvac013

2. Zhang C, Xie B, Wang X, et al. Burden of heart failure in Asia, 1990–2019: findings from

the Global Burden of Disease Study 2019. *Public Health*. 2024;230:66-72.

doi:10.1016/j.puhe.2024.02.015

3. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the

Management of Heart Failure: A Report of the American College of

Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063

4. Kao G, Xu G, Zhang Y, Li C, Xiao J. Predictive value of quality of life as measured by

KCCQ in heart failure patients: A meta-analysis. *European Journal of Clinical*

Investigation. 2024;54(9):e14233. doi:10.1111/eci.14233

5. Garcia RA, Benton MC, Spertus JA. Patient-Reported Outcomes in Patients with

Cardiomyopathy. *Curr Cardiol Rep*. 2021;23(7):91. doi:10.1007/s11886-021-01511-5

6. Michelis KC, Grodin JL, Zhong L, et al. Discordance Between Severity of Heart Failure

as Determined by Patient Report Versus Cardiopulmonary Exercise Testing. *Journal of*

the American Heart Association. 2021;10(13):e019864. doi:10.1161/JAHA.120.019864

7. El-Sabawi BR, Al-Garadi MA, Steitz BD, et al. Predicting Heart Failure Outcomes Using

Patient-Reported Health Status. *JACC*. 2025;85(23):2253-2266.

doi:10.1016/j.jacc.2025.03.545

8.   Tomasoni D, Vitale C, Guidetti F, et al. The role of multimorbidity in patients with heart
failure across the left ventricular ejection fraction spectrum: Data from the Swedish Heart
Failure Registry. *European Journal of Heart Failure*. 2024;26(4):854-868.
doi:10.1002/ejhf.3112

9.   Denfeld QE, Winters-Stone K, Mudd JO, Gelow JM, Kurdi S, Lee CS. The prevalence of
frailty in heart failure: A systematic review and meta-analysis. *International Journal of*
Cardiology. 2017;236:283-289. doi:10.1016/j.ijcard.2017.01.153

10. Iida Y, Kamiya K, Adachi T, et al. Prognostic impact of nutrition measures in patients
with heart failure varies with coexisting physical frailty. *ESC Heart Failure*.
2023;10(6):3364-3372. doi:10.1002/ehf2.14519

11. Lam CSP, Teng THK, Tay WT, et al. Regional and ethnic differences among patients with
heart failure in Asia: the Asian sudden cardiac death in heart failure registry. *Eur Heart J*.
2016;37(41):3141-3153. doi:10.1093/eurheartj/ehw331

12. Yoo SGK, Ahmed MO, Sweitzer NK. Current and Future of Heart Failure Care in Asia.
International Journal of Heart Failure. 2024;6(4):141-148. doi:10.36628/ijhf.2024.0033

13. Bourgeois FT, Orenstein L, Ballakur S, Mandl KD, Ioannidis JPA. Exclusion of Elderly
People from Randomized Clinical Trials of Drugs for Ischemic Heart Disease. *Journal of*
the American Geriatrics Society. 2017;65(11):2354-2361. doi:10.1111/jgs.14833

14. Elm E von, Altman DG, Egger M, et al. The Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting
Observational Studies. *PLOS Medicine*. 2007;4(10):e296.
doi:10.1371/journal.pmed.0040296

15. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and

treatment of acute and chronic heart failure: Developed by the Task Force for the

diagnosis and treatment of acute and chronic heart failure of the European Society of

Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA)

of the ESC. *European Heart Journal*. 2021;42(36):3599-3726.

doi:10.1093/eurheartj/ehab368

16. Spertus JA, Jones PG. Development and Validation of a Short Version of the Kansas City

Cardiomyopathy Questionnaire. *Circulation: Cardiovascular Quality and Outcomes*.

2015;8(5):469-476. doi:10.1161/CIRCOUTCOMES.115.001958

17. Green SB. How Many Subjects Does It Take To Do A Regression Analysis. *Multivariate*

Behavioral Research. 1991;26(3):499-510. doi:10.1207/s15327906mbr2603_7

18. World Medical Association. World Medical Association Declaration of Helsinki: Ethical

Principles for Medical Research Involving Human Subjects. *JAMA*. 2013;310(20):2191-

2194. doi:10.1001/jama.2013.281053

19. Thành NT, Thanh NX, Hương NTT, Thắng P, Huyền VTT. 23. TÍNH TIN CẬY VÀ GIÁ

TRỊ CỦA THANG ĐO KCCQ-12 ĐỂ ĐÁNH GIÁ CHẤT LƯỢNG CUỘC SỐNG Ở

BỆNH NHÂN SUY TIM MẠN TÍNH. *YHCĐ*. 2023;64(5). doi:10.52163/yhc.v64i5.780

20. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty

in elderly people. *CMAJ*. 2005;173(5):489-495. doi:10.1503/cmaj.050051

21. Caraballo C, Desai NR, Mulder H, et al. Clinical Implications of the New York Heart

Association Classification. *Journal of the American Heart Association*.

2019;8(23):e014240. doi:10.1161/JAHA.119.014240

22. Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City

Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care. *JACC*.

2020;76(20):2379-2390. doi:10.1016/j.jacc.2020.09.542

23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying

prognostic comorbidity in longitudinal studies: Development and validation. *Journal of*

Chronic Diseases. 1987;40(5):373-383. doi:10.1016/0021-9681(87)90171-8

24. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of Illness in the Aged:

The Index of ADL: A Standardized Measure of Biological and Psychosocial Function.

JAMA. 1963;185(12):914-919. doi:10.1001/jama.1963.03060120024016

25. Kaiser MJ, Bauer JM, Ramsch C, et al. Validation of the Mini Nutritional Assessment

short-form (MNA®-SF): A practical tool for identification of nutritional status. *The*

Journal of nutrition, health and aging. 2009;13(9):782-788. doi:10.1007/s12603-009-

0214-7

26. Coats AJS. Origins of Symptoms in Heart Failure. *Cardiovasc Drugs Ther*.

1997;11(1):265-272. doi:10.1023/A:1007739830030

27. Seiler M, Bowen TS, Rolim N, et al. Skeletal Muscle Alterations Are Exacerbated in

Heart Failure With Reduced Compared With Preserved Ejection Fraction. *Circulation:*

Heart Failure. 2016;9(9):e003027. doi:10.1161/CIRCHEARTFAILURE.116.003027

28. Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019

Consensus Update on Sarcopenia Diagnosis and Treatment. *Journal of the American*

Medical Directors Association. 2020;21(3):300-307.e2. doi:10.1016/j.jamda.2019.12.012

29. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for Cardiac Chamber

Quantification by Echocardiography in Adults: An Update from the American Society of

Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J*

Cardiovasc Imaging. 2015;16(3):233-271. doi:10.1093/ehjci/jev014

30. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and

short-term prognosis in acute destabilized heart failure: an international pooled analysis

of 1256 patients: The International Collaborative of NT-proBNP Study. *Eur Heart J*.

2006;27(3):330-337. doi:10.1093/eurheartj/ehi631

31. Fried LP, Tangen CM, Walston J, et al. Frailty in Older Adults: Evidence for a Phenotype.

J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-M157. doi:10.1093/gerona/56.3.M146

32. Rockwood K, Mitnitski A. Frailty in Relation to the Accumulation of Deficits. *J Gerontol*

A Biol Sci Med Sci. 2007;62(7):722-727. doi:10.1093/gerona/62.7.722

33. Regitz-Zagrosek V. Sex and Gender Differences in Heart Failure. *International Journal*

of Heart Failure. 2020;2(3):157-181. doi:10.36628/ijhf.2020.0004

34. Eastwood JA, Moser DK, Riegel BJ, et al. Commonalities and differences in correlates of

depressive symptoms in men and women with heart failure. *Eur J Cardiovasc Nurs*.

2012;11(3):356-365. doi:10.1177/1474515112438010

35. Lam CSP. Heart failure in Southeast Asia: facts and numbers. *ESC Heart Failure*.

2015;2(2):46-49. doi:10.1002/ehf2.12036

Tables

531   **Table 1**

Characteristic	Total (n = 150)	HFrEF (n = 54)	HFmrEF (n = 23)	HFpEF (n = 73)	p-value
Demographics, behavioural factors, and anthropometric measures					
Age (years), median (IQR)	75 (66–84)	70 (65–80)	71 (66–82)	77 (69–85)	0.001[a]
Age group, n (%)					0.005[a]
60-69 years	56 (37.3)	27 (50.0)	10 (43.5)	19 (26.0)	
70-79 years	41 (27.3)	13 (24.1)	6 (26.1)	22 (30.1)	
≥80 years	53 (35.3)	14 (25.9)	7 (30.4)	32 (43.8)	
Male sex, n (%)	89 (59.3)	34 (63.0)	15 (65.2)	40 (54.8)	0.336[b]
Current smoker, n (%)	51 (34.0)	19 (35.2)	9 (39.1)	23 (31.5)	0.642[b]
Current drinker, n (%)	57 (38.0)	24 (44.4)	9 (39.1)	24 (32.9)	0.183[b]
BMI (kg/m^2), mean (SD)	21.6 (2.2)	21.9 (2.3)	21.4 (2.2)	21.4 (2.1)	0.156[a]
BMI stratification, n (%)					0.072[a]
Underweight	15 (10.0)	3 (5.6)	2 (8.7)	10 (13.7)	
Normal	102 (68.0)	35 (64.8)	17 (73.9)	50 (68.5)	
Overweight	26 (17.3)	15 (27.8)	2 (8.7)	9 (12.3)	
Obese	7 (4.7)	1 (1.9)	2 (8.7)	4 (5.5)	
Vital signs and biomarkers					
HR (bpm), median	79 (65–91)	79 (65–91)	65 (63–89)	85 (68–91)	0.420[a]

(IQR)					
SBP (mmHg), mean (SD)	139 (12.0)	140 (12.4)	138 (12.6)	140 (11.6)	0.815[a]
DBP (mmHg), mean (SD)	85 (8.1)	85 (7.9)	86 (9.1)	85 (8.1)	0.875[a]
NT-proBNP (pg/mL), median (IQR)	604 (154–2122)	573 (213–2112)	654 (124–2125)	623 (158–2122)	0.973[a]
Cardiac and functional status					
LVEF (%), median (IQR)	49 (37–66)	35 (31–38)	45 (43–48)	67 (58–72)	<0.001[a]
NYHA functional class, n (%)					0.613[a]
I and II	107 (71.3)	38 (70.4)	20 (87.0)	49 (67.1)	
III and IV	43 (28.7)	16 (29.6)	3 (13.0)	24 (32.9)	
Geriatric syndromes and functional assessment					
Frailty, n (%)	54 (36.0)	19 (35.2)	5 (21.7)	30 (41.1)	0.438[b]
ADL limitation, n (%)	38 (25.3)	12 (22.2)	3 (13.0)	23 (31.5)	0.203[b]
Nutrition status, n (%)					0.240[a]
Malnourished	87 (58.0)	28 (51.9)	13 (56.5)	46 (63.0)	
At risk of malnutrition	52 (34.7)	21 (38.9)	10 (43.5)	21 (28.8)	
Normal	11 (7.3)	5 (9.3)	0 (0.0)	6 (8.2)	
Comorbidity burden					
CCI, median (IQR)	7 (5–8)	6 (5–8)	6 (5–8)	7 (5–9)	0.257[a]

CCI stratification, n (%)					0.217[a]
Low burden	47 (31.3)	16 (29.6)	10 (43.5)	21 (28.8)	
Medium burden	41 (27.3)	21 (38.9)	3 (13.0)	17 (23.3)	
High burden	62 (41.3)	17 (31.5)	10 (43.5)	35 (47.9)	
Polypharmacy, n (%)	132 (88.0)	50 (92.6)	23 (100.0)	59 (80.8)	0.033[b]
Comorbidity, n (%)					
Hypertension	137 (91.3)	49 (90.7)	22 (95.7)	66 (90.4)	0.910[b]
CAD	116 (77.3)	43 (79.6)	16 (69.6)	57 (78.1)	0.882[b]
Atrial fibrillation	43 (28.7)	7 (13.0)	4 (17.4)	32 (43.8)	<0.001[b]
Diabetes	72 (48.0)	29 (53.7)	9 (39.1)	34 (46.6)	0.460[b]
Dyslipidaemia	115 (76.7)	42 (77.8)	15 (65.2)	58 (79.5)	0.761[b]
CKD	43 (28.7)	17 (31.5)	4 (17.4)	22 (30.1)	0.930[b]
Stroke	9 (6.0)	3 (5.6)	1 (4.3)	5 (6.8)	0.746[b]

Abbreviations: ADL, activities of daily living; BMI, body mass index; CAD, coronary artery

disease; CCI, Charlson Comorbidity Index; CKD, chronic kidney disease; DBP, diastolic

blood pressure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart

failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction;

HR, heart rate; IQR, interquartile range; LVEF, left ventricular ejection fraction; n, number;

NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association;

SBP, systolic blood pressure; SD, standard deviation. [a]Jonckheere-Terpstra test; [b]Cochran-

Armitage test.

Table 2

Subgroup	KCCQ-12 overall summary scores	p-value
Total	68 (57–82)	--
HF phenotype		0.619a
HFrEF	70 (56–81)	
HFmrEF	72 (60–84)	
HFpEF	66 (56–81)	
NYHA functional class		<0.001[b]
I and II	78 (65–85)	
III and IV	52 (41–56)	
CCI stratification		<0.001[a]
Low burden	81 (77–89)	
Medium burden	70 (63–83)	
High burden	58 (43–63)	
Frailty		<0.001[b]
No	79 (65–85)	
Yes	55 (42–62)	
Age group		<0.001[a]
60-69 years	79 (65–85)	
70-79 years	76 (64–85)	
≥80 years	56 (50–64)	
Sex		0.001[b]
Female	63 (55–74)	
Male	76 (60–83)	

Abbreviations: CCI, Charlson Comorbidity Index; HFmrEF, heart failure with mildly reduced

ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure

with reduced ejection fraction; IQR, interquartile range; KCCQ-12, Kansas City

Cardiomyopathy Questionnaire-12; NYHA, New York Heart Association. Note: Data are

median (IQR). [a]Jonckheere-Terpstra test; [b]Mann-Whitney U test.

Table 3

Total (n = 150)		
Predictor	**Coefficient (95% CI)**	**p-value**
LVEF (per 1% increase)	0.02 (-0.06 to 0.11)	0.561
NYHA functional class (III and IV vs I and II)	-15.88 (-19.03 to -12.73)	<0.001
CCI (per 1 score increase)	-3.17 (-4.13 to -2.22)	<0.001
Frailty (yes vs. no)	-6.82 (-10.31 to -3.32)	<0.001
Age (per 1 increase)	-0.01 (-0.19 to 0.17)	0.909
Sex (male vs. female)	3.21 (0.32 to 6.10)	0.030
Model statistics		
R^2	0.767	
F-statistic	67.94	<0.001

548   *Abbreviations: CCI, Charlson Comorbidity Index; CI, confidence interval; LVEF, left*

549   *ventricular ejection fraction; n, number; NYHA, New York Heart Association; ref, reference;*

550   *VIF, variance inflation factor. Note: Diagnostic plots confirmed homoscedasticity, linearity,*

551   *and residual normality; mean VIF (1.53) indicated no multicollinearity.*

552 **Table 4**

Predictor	Coefficient (95% CI)	p-value
LVEF (per 1% increase)	0.02 (-0.07 to 0.10)	0.717
NYHA functional class (III and IV vs I and II)	-16.04 (-19.26 to -12.82)	<0.001
CCI (per 1 score increase)	-3.09 (-4.03 to -2.14)	<0.001
Frailty (yes vs. no)	-7.27 (-10.84 to -3.69)	<0.001
Age (per 1 increase)	-0.01 (-0.21 to 0.18)	0.878
Sex (male vs. female)	3.01 (0.15 to 5.87)	0.039
MNA-SF (per 1 point increase)	-0.35 (-0.76 to 0.06)	0.096
Model statistics		
R^2	0.771	
F-statistic (7, 142)	61.55	

553 *Abbreviations: CCI, Charlson Comorbidity Index; CI, confidence interval; LVEF, left*

554 *ventricular ejection fraction; MNA-SF, Mini Nutritional Assessment-Short Form; NYHA, New*

555 *York Heart Association; VIF, variance inflation factor. Note: Diagnostic plots confirmed*

556 *homoscedasticity, linearity, and residual normality; mean VIF (1.48) indicated no*

557 *multicollinearity.*

Table 5

Subgroup	Physical limitation scores	p-value	Symptom frequency scores	p-value	Quality of life scores	p-value	Social limitation scores	p-value
Total	67 (42–83)	--	73 (65–85)	--	50 (50–75)	--	75 (67–83)	--
HF phenotype		0.565		0.262		0.539		0.556
HFrEF	75 (42–75)		74 (65–85)		75 (50–75)		71 (67–83)	
HFmrEF	67 (50–83)		73 (70–94)		50 (50–75)		75 (67–92)	
HFpEF	58 (42–75)		73 (60–79)		50 (50–75)		67 (67–83)	
NYHA functional class		<0.001		<0.001		<0.001		<0.001
I and II	75 (58–83)		79 (70–92)		75 (50–75)		75 (67–92)	
III and IV	42 (25–42)		54 (42–67)		50 (38–50)		58 (50–67)	
CCI stratification		<0.001		<0.001		<0.001		<0.001
Low burden	83 (75–100)		85 (73–94)		75 (50–88)		83 (75–92)	
Medium burden	67 (58–75)		73 (67–85)		75 (50–75)		75 (67–83)	

High burden	42 (33–58)		65 (50–73)		50 (50–50)		67 (50–67)	
Frailty		<0.001		<0.001		<0.001		<0.001
No	75 (58–83)		79 (70–92)		75 (50–88)		75 (67–92)	
Yes	42 (33–58)		60 (44–70)		50 (50–50)		63 (50–67)	
Age group		<0.001		<0.001		<0.001		<0.001
60-69 years	75 (58–83)		79 (70–93)		75 (50–75)		83 (67–92)	
70-79 years	75 (58–83)		73 (67–92)		75 (50–88)		75 (67–83)	
≥80 years	42 (42–58)		65 (50–70)		50 (50–75)		67 (58–67)	
Sex		0.011		0.001		0.002		<0.001
Female	58 (42–75)		70 (58–73)		50 (50–75)		67 (58–75)	
Male	75 (50–83)		75 (67–92)		75 (50–75)		75 (67–83)	

559 Abbreviations: CCI, Charlson Comorbidity Index; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with

560 preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IQR, interquartile range; KCCQ-12, Kansas City

561 Cardiomyopathy Questionnaire-12; NYHA, New York Heart Association. Note: Data are median (IQR).

562   **Table 6**

Predictor	HFrEF (n = 54)		HFmrEF (n = 23)		HFpEF (n = 73)	
	Coefficient (95% CI)	p-value	Coefficient (95% CI)	p-value	Coefficient (95% CI)	p-value
NYHA functional class (III and IV vs. I and II)	-18.18 (-23.94 to -12.41)	<0.001	-14.95 (-38.43 to 8.54)	0.197	-17.30 (-21.24 to -13.34)	<0.001
CCI (per 1 score increase)	-2.25 (-3.66 to -0.84)	0.002	-7.00 (-10.35 to -3.65)	<0.001	-2.80 (-4.27 to -1.32)	<0.001
Frailty (yes vs. no)	-9.61 (-15.29 to -3.92)	0.001	-0.80 (-14.60 to 13.00)	0.904	-6.07 (-11.01 to -1.13)	0.017
Age (per 1 increase)	0.04 (-0.23 to 0.31)	0.768	0.31 (-0.46 to 1.09)	0.405	-0.02 (-0.31 to 0.27)	0.897
Sex (male vs. female)	0.45 (-4.77 to 5.66)	0.864	0.36 (-8.41 to 9.12)	0.933	6.21 (1.89 to 10.53)	0.006
Model statistics						
R^2	0.800		0.713		0.791	
F-statistic	32.62		10.74		43.81	

563   *Abbreviations: CCI, Charlson Comorbidity Index; CI, confidence interval; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF,*

564   *heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; n, number; NYHA, New York Heart*

565   *Association; VIF, variance inflation factor. Note: Diagnostic plots confirmed homoscedasticity, linearity, and residual normality for all*

566   *subgroups; mean VIFs (HFrEF 1.61; HFmrEF 2.68; HFpEF 1.78) indicated no multicollinearity.*

567 **Table 7**

Predictor	Interaction p-value
NYHA functional class	0.766
CCI	0.005
Frailty	0.198
Age	0.464
Sex	0.985

568 *Abbreviations: CCI, Charlson Comorbidity Index; NYHA, New York Heart Association.*